Oppenheimer raised the firm’s price target on Ascendis Pharma (ASND) to $262 from $246 and keeps an Outperform rating on the shares following quarterly results. Management reiterated expectations for this year’s operating cash flows to reach EUR 500M ex-TransCon CNP, for which the firm anticipates U.S. achondroplasia approval by the February 28 FDA action date and EU approval in Q4.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma price target raised to $325 from $256 at Stifel
- Ascendis Pharma price target raised to $256 from $250 at Morgan Stanley
- Ascendis Pharma: Strong Yorvipath Momentum, Pipeline Upside, and Raised DCF Assumptions Underpin Buy Rating and $260 Target
- Ascendis Pharma: Accelerating Commercial Momentum and Pipeline Execution Support Higher Target and Buy Rating
- ASND: Strong Yorvipath Momentum and Pipeline Catalysts Underpin Buy Rating and Long‑Term Upside